Assessing the viorologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 1, 2010, Pages 85-92

  Taiwo, Babafemi O ^a   Idoko, John A ^b   Welty, Leah J ^c   Otoh, Ihedinachi ^b   Job, Grace ^b   Iyaji, Paul G ^b   Agbaji, Oche ^b   Agaba, Patricia A ^b   Murphy, Robert L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF JOS   (Nigeria)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adherence; Sub Saharan Africa; Treatment partner; Virologic failure

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NIGERIA; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOCIAL SUPPORT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; NIGERIA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77951697280     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000371678.25873.1c     Document Type: Article

References (32)

1. Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among nä?ve HIV-1 infected individuals. AIDS. 2008;22:2371-2380.
2. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146;564-573.
3. Tuboi SH, Harrison LH, Sprinz E, et al. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr. 2005;40:324-328.
4. McNabb J, Ross JW, Abriola K, et al. Adherence to highly active anti-retroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33:700-705.
5. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and the selection of resistance-conferring mutations in NNRTI-or PI-treated patients. HIV Clin Trials. 2007;8: 282-292.
6. Roge BT, Barfod TS, Kirk O, et al. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. HIV Med. 2004;5:344-351.
7. Ware NC, Idoko J, Kaaya S, et al. Explaining adherence successes in sub-Saharan Africa: an ethnographic study. PLoS Med. 2009;6:e1000011. Doi:10.1371/1/journal.pmed1000011.
8. Macalino GE, Mitty JA, Bazerman LB, et al. Modified directly observed therapy for the treatment of HIV-seropositive substance users: lessons learned from a pilot study. Clin Infect Dis. 2004;38(Suppl 5):S393-S397.
9. Koenig SP, Leandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS. 2004; 18(Suppl 3):S21-S25.
10. Mukherjee JS, Ivers L, Leandre F, et al. Antiretroviral therapy in resource poor settings. Decreasing barriers to access and promoting adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S123-S126.
11. Farmer P, Leandre F, Mukherjee J, et al. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Organ. 2001;79:1145-1151.
12. Weidle PJ, Wamai N, Solberg P, et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet. 2006; 368:1587-1594.
13. Pearson CR, Micek MA, Simoni JM, et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr. 2007;46:238-244.
14. Sarna A, Luchters S, Geibel S, et al. Short-and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial. J Acquir Immune Defic Syndr. 2008;48: 611-619.
15. Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45:1492-1498.
16. Idoko JA, Agbaji O, Agaba P, et al. Direct observation therapy-highly active antiretroviral therapy in a resource-limited setting: the use of community treatment support can be effective. Int J STD AIDS. 2007;18: 760-763.
17. Petersen M, Wang Y, van der Laan M, et al. Pillbox organizers are associated with improved adherence to HIVantiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis. 2007; 45:908-915.
18. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
19. Steiner JF, Koepsell TD, Fihn SD, et al. A general method compliance assessment using centralized pharmacy records: description and validation. Med Care. 1988;26:814-823.
20. Ostrop NJ, Hallett KA, Gill MJ. Long-term patient adherence to antiretroviral therapy. Ann Pharmacother. 2000;34:703-709.
21. Nachega J, Goliath R, Efron A, et al. Randomized trial of trained patient-nominated treatment supporters providing directly observed ART in South African adults initiating HIV therapy. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada. Oral Abstract 143.
22. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006; 296:679-690.
23. Bisson GP, Rowh A, Weinstein R, et al. Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr. 2008;49:107-110.
24. Grossberg R, Zhang W, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57:1107-1110.
25. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival n HIV-1 infected South African adults. J Acquir Immune Defic Syndr. 2006; 43:78-84.
26. Bisson GP, Gross R, Bellamy S, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLos Med. 2008;5(5):e109. Doi:10.1371/journal. pmed.0050109.
27. Nachega JB, Hislop M, Dowdy D, et al. Adherence to non-nucleoside reverse transcriptase-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564-573.
28. Bangsberg DR. Less than 95% adherence to NNRTI can lead to viral suppression. Clin Infect Dis. 2006:43;939-941.
29. Weiser SD, Guzman D, Riley ED, et al. Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clin Trials. 2004;5:278-287.
30. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
31. Carlucci JS, Kamanga A, Sheneberger R, et al. Predictors of adherence to antiretroviral therapy in rural Zambia. J Acquir Immune Defic Syndr. 2008;47:615-622.
32. Birbeck GL, Chomba E, Kvalsund M, et al. Antiretroviral adherence in rural Zambia: the first year of treatment availability. Am J Trop Med Hyg. 2009;80:669-674.